
‘It had teeth': A 3-year-old discovers ancient treasure in Israel
Naturally, Ziv picked it up. When she rubbed off the dirt, 'she noticed that it was something very special,' said her mother, Sivan Nitzan.
The alluring pebble turned out to be a 3,800-year-old Egyptian amulet, engraved with the design of an insect known as a scarab and dating from the Bronze Age, according to the Israel Antiquities Authority, which later collected it.
It wasn't the first time that a young hiker had stumbled upon an archaeological treasure in Israel, given its rich history.
Advertisement
Last year, while on a hike on Mount Carmel in Haifa, a 13-year-old boy found a Roman-era ring with an engraving of the goddess Minerva. In 2016, a 7-year-old boy on a trip with friends in the Beit She'an Valley discovered a well-preserved, 3,400-year-old carving of a nude woman. And many sharp-eyed children have unearthed coins made during periods of Roman or Hasmonean rule.
But Ziv is the youngest child known to have discovered an ancient artifact in Israel, said Yoli Schwartz, a spokesperson for the antiquities authority, who called the find 'very exciting.'
Ziv found the relic near Tel Azekah, an archaeological site and an area described in the Bible as the site of the battle between David and Goliath.
Advertisement
The amulet most likely belonged to the Canaanites, a group of Semitic people who lived in the area around 1800 B.C., said Oded Lipschits, a professor of Jewish history at Tel Aviv University who is leading an excavation at Tel Azekah. The Canaanites, like others in the region at the time, were interested in all things Egyptian, he said, and they often imported or imitated their food, style and luxury items — including seals like the one that Ziv found, which were worn like jewelry as personal talismans.
Scarabs, or dung beetles, were particularly popular in talismans at the time because they were a symbol of rebirth, the antiquities authority said in a statement. (The insects lay their eggs in balls of dung, from which a new generation emerges.) Ziv's scarab relic was most likely created in Egypt and then found its way to modern-day Israel around 3,800 years ago, Lipschits said.
But how did it end up on a hiking trail where a child could find it?
Lipschits offered an explanation.
In 1898, two British archaeologists began excavating Tel Azekah — one of the first biblical sites to be exhumed in Israel — where they found an acropolis, walls of a citadel and artifacts from pre-Israelite cultures. When they were done, the man who owned the land asked them to fill the hole they had excavated so he could farm the area, Lipschits said.
'So the modern layers are now inside, and the old layers that used to be very deep in the ground are now on the surface,' he explained. 'And this is why people can find all kinds of ancient items like these scarabs on the surface.'
Advertisement
Children also make excellent amateur archaeologists, Lipschits added, because they're curious, low to the ground, and unafraid to get their hands dirty.
In itself, the amulet that Ziv picked up 'was not so exceptional,' Lipschits said — his team has uncovered dozens of similar scarabs in the area, some of higher quality. What is more important, he said, is that the family handed it over to the Israel Antiquities Authority so that it could be preserved and everyone could enjoy it.
'If she put it in her pocket and kept it, we wouldn't know about it,' Schwartz said. 'We're very happy to show it to the public.'
The authority gave Ziv a certificate of appreciation for 'good citizenship.' The amulet she found will be included in an upcoming exhibition of Canaanite and Egyptian artifacts at the Jay and Jeanie Schottenstein National Campus for the Archaeology of Israel in Jerusalem.
This article originally appeared in
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Yahoo
14 hours ago
- Yahoo
'America's AI Arsenal Just Went Live': AI Insider Briefs Public on Secret Supercomputer Built by Musk
BALTIMORE, June 05, 2025 (GLOBE NEWSWIRE) -- A newly surfaced report from bestselling author and tech insider James Altucher outlines the existence of a massive U.S.-based artificial intelligence weapon — one that could redefine America's global standing in the AI arms race. According to Altucher, the project — code-named Project Colossus — is being built by Elon Musk's company xAI, in coordination with recent policy changes made by the Trump administration. Housed in a low-profile facility in Memphis, Tennessee, Altucher says this machine is already operational — and growing more powerful by the day. 'The Fastest Supercomputer on the Planet' The briefing claims the facility is equipped with 200,000 cutting-edge AI chips, making it the most powerful computing center in the Western Hemisphere. 'It contains not just one or two… but 200,000 units of Nvidia's all-powerful AI chips… making it the most advanced AI facility known to man.' 'The fastest supercomputer on the planet.' — Jensen Huang, Nvidia CEO Altucher notes that Musk plans to expand this further in the coming weeks, with rumors of additional hardware that could multiply its power tenfold. Trump Cleared the Runway The report links the timing of Project Colossus to a major political shift. On Day 1 of his second term, Donald Trump reversed Biden-era restrictions on AI development. 'In one of his FIRST acts as President… Donald Trump overturned Executive Order #14110.' Altucher claims this decision allowed developers like Musk to operate 'without red tape or delay' — accelerating America's path toward dominance in the next generation of AI systems. Altucher: This Is 'Artificial Superintelligence' Altucher describes this moment not as another software release — but a seismic shift in how technology operates. 'This second wave of ARTIFICIAL SUPERINTELLIGENCE… Will rival all of the great innovations of the past. Electricity… the wheel… even the discovery of fire.' His report urges Americans to understand what's unfolding — not just in Silicon Valley, but in unmarked warehouses like the one now powering Project Colossus. About James Altucher James Altucher is a computer scientist, entrepreneur, and author who has worked on AI projects for over 40 years. A former IBM consultant and Wall Street technologist, he now focuses on breaking down emerging tech developments for a general audience. His latest briefing examines how Artificial Superintelligence is reshaping U.S. strategy and infrastructure. Media Contact:Derek WarrenPublic Relations ManagerParadigm Press GroupEmail: dwarren@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
16 hours ago
- Medscape
Combination Therapy Offers CONFIDENCE to CKD+T2D Patients
VIENNA — Combining the SGLT2 inhibitor empagliflozin with finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), markedly and durably reduced albuminuria in patients with both chronic kidney disease (CKD) and type 2 diabetes (T2D), the CONFIDENCE trial showed in findings that offer hope of a long-term improvement in outcomes. In the trial, 70% of patients on both therapies achieved the American Diabetes Association recommended urinary albumin-to-creatinine ratio (UACR) reduction target of > 30%. 'Since UACR is a key mediator of kidney and cardiovascular outcomes, these results are highly relevant for clinical decision-making,' said lead researcher Rajiv Agarwal, MD, MS, professor emeritus of medicine, Indiana University School of Medicine, Indianapolis. The results were presented here at the 62nd European Renal Association (ERA) Congress 2025 on June 5 and sparked enthusiastic applause from the audience. The findings were simultaneously published in The New England Journal of Medicine. Agarwal, who shared the podium with three of his co-investigators to present the study, added that this was in keeping with 'other chronic conditions like heart failure or hypertension,' in that 'we're moving away from the traditional stepwise approach toward upfront combination therapy.' Session co-chair Mustafa Arici, MD, professor of medicine (nephrology), Hacettepe University, Ankara, Turkey, described the results as 'remarkable.' He told Medscape Medical News , 'For protecting the kidneys of type 2 diabetes patients, it looks like we now have the data to start an SGLT2 inhibitor plus an MRA in combination from the first day, because the data is very solid.' Arici noted, however, that the study did not include clinical endpoints and 'people usually would like to hear solid outcomes. We would like to see whether the number of dialyses decreased or the mortality decreased.' But — as the presenters themselves pointed out — the numbers required to show a clinical benefit are too large to feasibly conduct a trial, he said. 'Obviously there is a surrogate outcome here, which is the UACR,' said Arici. "And at the moment, we have data from 800 people with a good amount of follow up and with no safety signal, which is important." Implementing and Combining Additional Drugs Co-investigator of the CONFIDENCE study, Peter Rossing, MD, PhD, clinical professor, Steno Diabetes Center, Copenhagen, Denmark, noted that, in terms of treatment, the standard of care in patients with CKD and T2D is based on four pillars, with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) joined in recent years by SGLT2 inhibitors, MRAs, and GLP-1 receptor agonists. 'However, we do not know really how to implement these additional drugs and how to combine them,' Rossing said. Clues have come from combination trials in hypertension and heart failure with reduced ejection fraction, which led to the evolution of guideline recommendations and the mantra that, when it comes to using multiple drugs, it is better to give 'some of all, instead of all of some.' A recent analysis also suggested that steroidal MRAs and SGLT2 inhibitors may have additive effects in reducing UACR, far more than either drug alone, although only 32 patients in the study had both CKD and T2D. In the current trial, patients were enrolled if they had: a UACR of ≥ 100 – < 5000 mg/g; an estimated glomerular filtration rate (eGFR) of 30-90 mL/min/1.73 m2; T2D with an A1c < 11%; and were receiving clinically maximally tolerated doses of ACE inhibitors/ARBs for > 1 month. The participants were randomly assigned to one of three groups: simultaneous finerenone plus empagliflozin; finerenone plus placebo; or empagliflozin plus placebo. Patients were treated for 180 days, with clinical visits on days 14, 30, and 90, and then went through a washout period through to day 210. Choosing a composite kidney endpoint for the primary efficacy analysis would have required 41,000 patients to be enrolled into the trial, explained co-investigator Hiddo J.L. Heerspink, PhD, Department of Clinical Pharmacology, University Medical Center, Groningen, Netherlands. Instead, the researchers opted for the more feasible primary endpoint of relative change in UACR from baseline to day 180, as previous studies have shown that short-term UACR changes are associated with kidney protection in the long term. In all, 818 patients were randomly assigned from 143 sites in 14 countries, of whom 269 ended up receiving the combination therapy, 264 had finerenone monotherapy, and 267 were treated with empagliflozin alone. The mean age of the patients was 67 years, and 75% were male. Forty-six percent were Asian and 44% were White. Turning to the efficacy analysis, Agarwal asked the audience to vote on the percentage reduction in UACR that they expected the combination therapy would achieve. The most common answer, chosen by 37.7% of voters, was 30%-40%. Agarwal then showed that, in fact, combining finerenone with empagliflozin achieved a 52% reduction in UACR over baseline, 32% greater than that seen with empagliflozin alone, and 29% greater than that seen with finerenone monotherapy. 'It's great to see some positive trial results,' he added, in response to the audience's acclamation. In addition, only 52% of patients treated with either drug alone reached a > 30% reduction in UACR at day 180 compared to the 70% of patients treated with the combination. In addition, a total of 64% of patients treated with the combination achieved a > 40% reduction in UACR, and 55% reached a > 50% reduction. In both cases, the proportions of patients reaching the target with monotherapy were approximately 20% lower. The benefit in terms of serum potassium levels was also notable, as there was a 17.7% reduction in the incidence of treatment-emergent hyperkalemia, defined as serum levels > 5.5 mmol/L, with combination therapy vs finerenone monotherapy. Agarwal also noted that there was a low incidence of hypotension with combination therapy, with just three cases (1.1%), and a low incidence of acute kidney injury, at five cases (1.9%). There was an initial decline in eGFR, which was described as 'predictable' and largely reversible after drug withdrawal. Crucially, the researchers also showed that during the washout period, UACR levels returned to almost those seen at baseline. This pattern was also observed with the marked improvements in both serum potassium and blood pressure levels that were seen with finerenone plus empagliflozin, which were again greater than those achieved with either monotherapy. After the data were presented, study co-investigator Johannes F.E. Mann, MD, head, KfH Kidney Center, Munich, Germany, sought to explain the implications of the findings by pointing to a recent mediation analysis of pooled data from two phase 3, double-blind trials of finerenone. This revealed that reductions in UACR over the first 4 months of treatment explained 84% of the later reductions in kidney progression and 37% of the reductions in cardiovascular outcomes, suggesting that the findings from CONFIDENCE may well translate into later improvements in clinical endpoints. Muthiah Vaduganathan, MD, MPH, from the Department of Cardiovascular Medicine at Brigham and Women's Hospital, Boston, welcomed the findings. Commenting on X (formerly Twitter), he said that the simultaneous initiation of the combination therapy 'safely and rapidly delivers' in patients with both CKD and T2D. 'A new age of combination therapies has arrived.' The study was funded by Bayer. Agarwal declares relationships with Akebia Therapeutics, Alnylam, Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Intercept, Novartis, UpToDate, Wolters Kluwer, Chinook, and Vertex. Rossing declares relationships with AstraZeneca, Bayer, Novo Nordisk, Abbott, Astellas, Boehringer Ingelheim, Eli Lilly, Gilead, Sanofi, Daiichi Sankyo, and Lexicon Pharma. Heerspink declares relationships with Alexion, AstraZeneca, Bayer, Boehringer Ingelheim, BioCity, Dimerix, Eli Lilly, Janssen, Novartis, Novo Nordisk, Roche, and Travere Therapeutics. Mann declares relationships with Novo Nordisk, the European Union, Bayer, AstraZeneca, Bayer, Novartis, UpToDate, Cytel, IQVIA, Parexel, WCG, and Sanofi.

Yahoo
16 hours ago
- Yahoo
'America's AI Arsenal Just Went Live': AI Insider Briefs Public on Secret Supercomputer Built by Musk
BALTIMORE, June 05, 2025 (GLOBE NEWSWIRE) -- A newly surfaced report from bestselling author and tech insider James Altucher outlines the existence of a massive U.S.-based artificial intelligence weapon — one that could redefine America's global standing in the AI arms race. According to Altucher, the project — code-named Project Colossus — is being built by Elon Musk's company xAI, in coordination with recent policy changes made by the Trump administration. Housed in a low-profile facility in Memphis, Tennessee, Altucher says this machine is already operational — and growing more powerful by the day. 'The Fastest Supercomputer on the Planet' The briefing claims the facility is equipped with 200,000 cutting-edge AI chips, making it the most powerful computing center in the Western Hemisphere. 'It contains not just one or two… but 200,000 units of Nvidia's all-powerful AI chips… making it the most advanced AI facility known to man.' 'The fastest supercomputer on the planet.' — Jensen Huang, Nvidia CEO Altucher notes that Musk plans to expand this further in the coming weeks, with rumors of additional hardware that could multiply its power tenfold. Trump Cleared the Runway The report links the timing of Project Colossus to a major political shift. On Day 1 of his second term, Donald Trump reversed Biden-era restrictions on AI development. 'In one of his FIRST acts as President… Donald Trump overturned Executive Order #14110.' Altucher claims this decision allowed developers like Musk to operate 'without red tape or delay' — accelerating America's path toward dominance in the next generation of AI systems. Altucher: This Is 'Artificial Superintelligence' Altucher describes this moment not as another software release — but a seismic shift in how technology operates. 'This second wave of ARTIFICIAL SUPERINTELLIGENCE… Will rival all of the great innovations of the past. Electricity… the wheel… even the discovery of fire.' His report urges Americans to understand what's unfolding — not just in Silicon Valley, but in unmarked warehouses like the one now powering Project Colossus. About James Altucher James Altucher is a computer scientist, entrepreneur, and author who has worked on AI projects for over 40 years. A former IBM consultant and Wall Street technologist, he now focuses on breaking down emerging tech developments for a general audience. His latest briefing examines how Artificial Superintelligence is reshaping U.S. strategy and infrastructure. Media Contact:Derek WarrenPublic Relations ManagerParadigm Press GroupEmail: dwarren@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data